anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Flumazenil injection, USP is recommended for intravenous use only. It is compatible with 5% dextrose in water, lactated Ringer’s and normal saline solutions. If flumazenil injection is drawn into a syringe or mixed with any of these solutions, it should be discarded after 24 hours. For optimum sterility, flumazenil injection should remain in the vial until just before use. As with all parenteral drug products, flumazenil injection should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

To minimize the likelihood of pain at the injection site, flumazenil injection should be administered through a freely running intravenous infusion into a large vein.
Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
PURPOSE: Estrogen or progestogen pills previously on the market for commercial purpose can not be varied the daily dose of the estrogen or progestogen without physician's prescribing. As the rate of absorbing estrogen or progestogen pills is dependant on physical characteristics of each person, new hormone dispenser or coated-pills able to control the rate of absorption into body is needed. CONSTITUTION: Two containers equipped with a digitalized gauger and an extruding machine in each are provided, and each container have a chamber stored with estrogen and progestogen respectively, and estrogen and progestogen is mixed in a dispenser connected to each chamber. This pharmaceutical composition can be used in the form of gel, ointment, and creme. When a sheet or film is employed as the delivery surface for transporting the pharmaceutical compositions to the area of the skin selected for transdermal administration of the hormones, the sheet or film can also be used as a transdermal patch to extend the contact time of the compositions with the skin, When the mode of administration is oral, the delivery surface can be edible, such as a sheet of rice paper, or gelatin film so that the delivery surface as well as the extrudate thereon is ingested by the patient. This is useful when the extrudate is a viscous liquid or a sticky semi-solid.
The invention relates to a pressure-relieving rehabilitation paste which is externally pasted for treating primary hypertension. The pressure-relieving rehabilitation paste is externally-applied ointment prepared from the following traditional Chinese medicine raw materials in parts by weight by adding auxiliary materials: 5-100 parts of radix puerariae, 5-100 parts of motherwort, 5-100 parts of twotooth achyranthes root, 5-100 parts of rhizoma ligustici wallichii, 5-100 parts of loadstone, 5-200 parts of radix salviae miltiorrhizae, 5-100 parts of evodia rutaecarpa, 5-100 parts of self-heal, 5-100 parts of red peony root, 5-100 parts of rhizoma alismatis, 5-100 parts of giant mistletoe and 5-80 parts of borneol. The pressure-relieving rehabilitation paste is prepared by pulverizing the medicines, sieving by a sieve of 100 meshes evenly and disinfecting by ultraviolet rays. The pressure-relieving rehabilitation paste comprises the following auxiliary materials: vaseline, propylene glycol, azone, lanolin and methyl phydroxybenzoate ethyl ester which are prepared into the ointment. The pressure-relieving rehabilitation paste has the use method that the pressure-relieving rehabilitation paste is pasted and applied to the specific acupuncture points of a human body, such as four acupuncture points of Shenjue acupuncture point, Zhaohai acupuncture point, Xialiao acupuncture point and Dazhui acupuncture point. The invention has the functions of promoting blood circulation, relieving the stasis of blood, relieving spasm, lowering blood press, calming the mind, soothing the nerves and regulating the nerves and has obvious curative effect for primary hypertension.
Severe toxic effects of arsenic on human physiology have been of immense concern worldwide. Arsenic causes irrevocable structural and functional disruption of tissues, leading to major diseases in chronically exposed individuals. However, it is yet to be resolved whether the effects result from direct deposition and persistence of arsenic in tissues, or via activation of indirect signaling components. Emerging evidences suggest that gut inhabitants play an active role in orchestrating various aspects of brain physiology, as the gut-brain axis maintains cognitive health, emotions, learning and memory skills. Arsenic-induced dysbiosis may consequentially evoke neurotoxicity, eventually leading to anxiety and depression. To delineate the mechanism of action, mice were exposed to different concentrations of arsenic. Enrichment of Gram-negative bacteria and compromised barrier integrity of the gut enhanced lipopolysaccharide (LPS) level in the bloodstream, which in turn elicited systemic inflammation. Subsequent alterations in neurotransmitter levels, microglial activation and histoarchitectural disruption in brain triggered onset of anxiety- and depression-like behaviour in a dose-dependent manner. Finally, to confirm whether the neurotoxic effects are specifically a consequence of modulation of gut microbiota (GM) by arsenic and not arsenic accumulation in the brain, fecal microbiota transplantations (FMT) were performed from arsenic-exposed mice to healthy recipients. 16S rRNA gene sequencing indicated major alterations in GM population in FMT mice, leading to severe structural, functional and behavioural alterations. Moreover, suppression of Toll-like receptor 4 (TLR4) using vivo-morpholino oligomers (VMO) indicated restoration of the altered parameters towards normalcy in FMT mice, confirming direct involvement of the GM in inducing neurotoxicity through the arsenic-gut-brain axis. This study accentuates the potential role of the gut microbiota in promoting neurotoxicity in arsenic-exposed mice, and has immense relevance in predicting neurotoxicity under altered conditions of the gut for designing therapeutic interventions that will target gut dysbiosis to attenuate arsenic-mediated neurotoxicity.
Wound healing is a highly programmed process, in which any abnormalities result in scar formation. MicroRNAs are potent regulators affecting wound repair and scarification. However, the function of microRNAs in wound healing is not fully understood. Here, we analyzed the expression and function of microRNAs in patients with cutaneous wounds. Cutaneous wound biopsies from patients with either hypertrophic scarring or normal wound repair were collected during inflammation, proliferation, and remodeling phases. Fourteen candidate microRNAs were selected for expression analysis by qRT-PCR. The expression of genes involved in inflammation, angiogenesis, proliferation, and migration were measured using qRT-PCR. Cell cycle and scratch assays were used to explore the proliferation and migration rates. Flow cytometry analysis was employed to examine TGF-β, αSMA and collagen-I expression. Target gene suggestion was performed using Enrichr tool. The results showed that miR-16-5p, miR-152-3p, miR-125b-5p, miR-34c-5p, and miR-182-5p were revealed to be differentially expressed between scarring and non-scarring wounds. Based on the expression patterns obtained, miR-182-5p was selected for functional studies. miR-182-5p induced RELA expression synergistically upon IL-6 induction in keratinocytes and promoted angiogenesis. miR-182-5p prevented keratinocyte migration, while overexpressed TGF-β3 following induction of inflammation. Moreover, miR-182-5p enhanced fibroblast proliferation, migration, differentiation, and collagen-1 expression. FoxO1 and FoxO3 were found to potentially serve as putative gene targets of miR-182-5p. In conclusion, miR-182-5p is differentially expressed between scarring and non-scarring wounds and affect the behavior of cells involved in cutaneous wound healing. Deregulated expression of miR-182-5p adversely affects the proper transition of wound healing phases, resulting in scar formation.
Participants with R/R non-APL AML or R/R HR-MDS will receive tamibarotene at 6 mg/m\^2/day in 2 divided doses during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants will also receive daratumumab at 16 mg/kg starting on Cycle 1 Day 1 once weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks.
BACKGROUND: Increased intracranial pressure (ICP) in patients with hypertensive intracerebral hemorrhage (HICH) has been associated with poor prognosis. The transsylvian insular approach (TIA) and the transcortical (TCA) approach are applied for patients with HICH. We aimed to compare the postoperative ICP parameters of TIA and TCA to identify which procedure yields better short-term outcomes in patients with basal ganglia hematoma volumes ranging from 30 to 50 mL.
METHODS: Eighty patients with basal ganglia hematomas 30-50 mL were enrolled in this study. Patients were implanted with ICP probes and divided into TIA and TCA groups according to the procedure. The ICP values were continuously recorded for five days at four-hour intervals. Short-term outcomes were evaluated using the length of hospitalization and postoperative consciousness recovery time.
RESULTS: No statistically significant differences were found in age, sex, GCS score at admission, hematoma volume, and hematoma clearance rate (p > 0.05). The results showed that postoperative initial ICP, ICP on the first postoperative day, mean ICP, DICP20 mmHg × 4 h, postoperative consciousness recovery time, the length of hospitalization, mannitol utilization rate and the mannitol dosage were lower in the TIA group than in the TCA group (p < 0.05). Postoperative consciousness recovery time was positively correlated with ICP on the first postoperative day, and the length of hospitalization was positively correlated with mean ICP.
CONCLUSIONS: TIA is more effective than TCA in improving the short-term outcomes of patients with basal ganglia hematoma volumes ranging from 30 to 50 mL according to comparisons of postoperative ICP parameters.
A pharmaceutical preparation containing ibuprofen is disclosed. In the preparation, the ibuprofen particles are enveloped by a coating of a hydro-colloid and fumaric acid. Preferably, the hydro-colloid comprises xanthan gum and/or maltodextrin. This preparation reduces the tendency of ibuprofen to irritate the esophagus and the gastrointestinal tract when taken orally. An effervescent mixture of the ibuprofen containing preparation can be prepared by incorporating citric acid and calcium carbonate into the mixture. A process for the manufacture of the ibuprofen containing preparation is also disclosed. In this process, ibuprofen particles are coated with the hydro-colloid and fumaric acid under vacuum conditions in a vacuum mixing machine and the resulting preparation is thereafter vacuum-dried.
Of the patients receiving ACTONEL in postmenopausal osteoporosis studies [see Clinical Studies (14)], 47% were between 65 and 75 years of age, and 17% were over 75. The corresponding proportions were 26% and 11% in glucocorticoid-induced osteoporosis trials, and 40% and 26% in Paget’s disease trials. No overall differences in efficacy between geriatric and younger patients were observed in these studies. In the male osteoporosis trial, 28% of patients receiving ACTONEL were between 65 and 75 years of age and 9% were over 75. The lumbar spine BMD response for ACTONEL compared to placebo was 5.6% for subjects <65 years and 2.9% for subjects ≥65 years. No overall differences in safety between geriatric and younger patients were observed in the ACTONEL trials, but greater sensitivity of some older individuals cannot be ruled out.
Diabetes is a chronic and a progressive metabolic disorder which necessitates active patient involvement to effectively manage nutrition, physical activity, and medication for optimal outcomes. Self-management is a critical aspect of diabetes care and a variety of studies have established the need for people with diabetes to be knowledgeable about their condition and be actively involved in its management to effectively reduce the risk of future health complications and improve other outcomes. Diabetes self-management education and support (DSMES) can help patients effectively engage in and perform their diabetes-related self-care activities. However, only a small number of patients with diabetes participate in DSMES. A few studies in this area have highlighted both physician and patient-related factors that could affect the receipt of DSMES. Patients' involvement in a DSMES program continues to be largely prompted by a physician referral and it has been suggested that improving physician involvement in the DSMES process could enhance overall patient engagement and adherence to such programs.

As part of the proposed mixed methods study, in Phase 1, in-depth surveys (or interviews) will be undertaken with: (a) physicians caring for people with type 2 diabetes, (b) DSMES providers (e.g., certified diabetes educators, diabetes nurses, dietitians), and (b) patients with type 2 diabetes regarding their perception of diabetes education programs, barriers, and facilitators to engagement. Findings from Phase 1 will be shared with the education team at a diabetes center in a community hospital in Orange County, California to inform changes to their currently existing diabetes education curriculum to make it more patient-centered and improve physician engagement and support. As part of Phase 2, the newly developed program will be implemented with a diverse cohort of 90 patients with type 2 diabetes. Patient participation (attendance) in the DSMES process will be documented as a primary marker of patient engagement while their clinical and psycho-social outcomes will serve as secondary indicators. Among other outcomes, physician, educator, and patient satisfaction with the newly developed referral process will also be assessed as a measure of intervention acceptability and success.
A location detection system for person support apparatuses includes multiple network wireless access points that communicate with a plurality of mobile transceivers positioned on board the person support apparatuses. Based upon signal strength data (e.g. RSSI or RCPI) of messages from the access points to the transceivers, the locations of the person support apparatuses are determined. In some embodiments, the person support apparatuses include an additional location detection system that utilizes fixed locators having short range transceivers to generate a second location determination of the person support apparatuses. In still other embodiments, the person support apparatuses utilize the second location detection system to determine the location of the wireless access points. The person support apparatuses may also broadcast their location to other devices that then utilize the received signal strengths of those messages to determine their own location.
PURPOSE:To obtain a bathing agent exhibiting the action and effect close to those of natural hot spring, imparting the skin with smooth feeling in bathing and giving refreshing feeling after bath, by adding a metal sequestering agent to sodium carbonate used as a main component. CONSTITUTION:A metal sequestering agent is added to a bathing agent composed mainly of Na2CO3 and exhibiting pH 9-10.5 when dissolved in bath water. The sequestering agent is sodium polyphosphate, sodium citrate, etc., and the amount is 0.1-10wt.% based on the whole bathing agent. The amount of Na2CO3 is 50-90wt.% based on the whole bathing agent. The concentration of Na2CO3 in the bath water should be adjusted to 30-300ppm, preferably 50-200ppm. The bathing agent does not precipitate powder on the bottom of bathtub, gives nearly transparent bath water and is suitable for person who does not like milk-white bath water.
Dengue viruses are a major health concern, particularly in the tropical and subtropical regions of the world. The World Health Organization (WHO) has made the development of a dengue vaccine a top priority. There are four types of dengue viruses (DEN1, DEN2, DEN3, and DEN4), each of which can cause various illnesses, including dengue fever, or the more severe disease, dengue hemorrhagic fever/shock syndrome (DHF/DSS). This study will evaluate the safety and immune response to two doses of a dengue virus vaccine (TV003) when administered 12 months apart in healthy adults. The study will also evaluate whether the candidate vaccine may protect against all four types of dengue viruses.

Participants will be randomly assigned to receive the TV003 study vaccine or placebo vaccine. At study entry, participants will undergo a blood collection and physical examination, and female participants will take a pregnancy test. Participants will then receive an injection of their assigned vaccine. They will take their temperature three times a day for 16 days after each vaccination and record the results on a diary card, which research staff will review during participants' study visits. Additional study visits will occur on Days 3, 10, 14, 21, 28, 56, 90, 180, 270, and 330. All study visits will include blood collection and a physical examination; select visits will include a pregnancy test for female participants. At a study visit on Day 360, all participants will receive an injection of the same vaccine they received at study entry. Additional study visits will occur on Days 363, 370, 374, 381, 388, 416, 450, and 540, and will include the same study procedures as previously performed.
PURPOSE:To provide a carcinostatic agent having proliferation suppressing effect to various tumors, by extracting dragon's blood with water or an organic solvent miscible freely with water, and using the extract as an active component. CONSTITUTION:Dragon's blood (rosin obtained from the fruit of Daemonorop draco) is extracted with water and/or an organic solvent miscible freely with water (e.g. methanol), and the extract is used as an active component of a carcinostatic agent. Dragon's blood contains a red pigment dracorubin (C32H24O5), and has been used as a stegnotic for antidiarrhetic or hemostatic use for a long time, and it has been newly found that the substance exhibits excellent effect to suppress the proliferation of experimental tumor, e.g. sarcoma 180 ascites tumor, Lewis lung carcinoma and ascites Yoshida sarcoma. It can be administered orally or parenterally. Dose: 5-150mg/day for oral administration and 0.1-30mg/day for parenteral administration.
BACKGROUND: Antiphospholipid syndrome (APS) is recognized as a thrombophilic autoimmune condition characterized by a tendency to develop venous thromboembolism. Total knee arthroplasty (TKA) is a prevalent procedure in patients who have advanced knee arthritis. Notably, TKA is unequivocally considered a thrombotic risk factor. However, outcomes of APS patients after TKA are still poorly documented in literature. The purpose of this study was to evaluate APS as a potential risk factor for complications after TKA.
METHODS: Using the PearlDiver Mariner database from 2010 to 2022, APS patients undergoing primary TKA were identified and compared to 10:1 matched control based on age, sex, and relevant comorbidities. A total of 7,478 patients undergoing primary TKA were analyzed, of which 683 had APS. Multivariable logistic regression analyses were done for medical complications up to 90 days and surgical complications including revision up to 2 years. Ninety-day emergency department visit and inpatient readmission were also documented.
RESULTS: Within 90 days after TKA, patients who have APS exhibited higher rates of cerebrovascular accident (adjusted odds ratio 2.04, 95% confidence interval 1.12 to 3.57; P = .014) and deep vein thrombosis (adjusted odds ratio 2.87, 95% confidence interval 1.99 to 4.06; P < .001) as compared to matched controls. No difference in surgical or nonthrombotic medical complications was observed between 2 cohorts.
CONCLUSIONS: There were significantly higher rates of stroke and deep vein thrombosis in APS patients. Our study did not find statistical differences in other surgical complications or readmissions between the 2 groups. Orthopaedic surgeons should consider appropriate prophylaxis of thrombosis in this patient population undergoing TKA perioperatively.
The invention discloses an anti-infective drug cefetamet pivoxil hydrochloride composite capsule and belongs to the technical field of drugs. A composite is prepared from cefetamet pivoxil hydrochloride, microcrystalline cellulose, magnesium aluminum silicate, povidone K30, anhydrous ethanol and magnesium stearate. The cefetamet pivoxil hydrochloride is a new crystal type compound. An X-ray powder diffraction diagram obtained through Cu-K alpha ray measurement is shown in figure one. The cefetamet pivoxil hydrochloride is different from cefetamet pivoxil hydrochloride reported in the prior art. As is found in experiments, the capsule prepared from the cefetamet pivoxil hydrochloride new crystal type compound is low in high-molecular polymer content and good in stability, and the content of high-molecular polymers is little increased along with prolonging of storage time. Meanwhile, the composite has more remarkable antibacterial activity on pneumococcus and hemophilus influenzae and also has high antibacterial activity on enterococcus and staphylococcus.
A method for creating and transmitting electronic medical data from a remote location, such as a battlefield, to a remotely located central data facility. The method can begin by entering the personal identification data for an injured person into a portable handheld computer. Responsive to voice commands, data input fields are selected and populated. The data can be inputted into the computer via a touch screen or via the microphone. A recording may be made, with a camera included in the portable handheld computer, of imagery associated with the injured person. Thereafter, an audio recording can be made, recording audio records concerning injuries or treatments of the injured person. Medical data obtained about the injury, as well as patient vitals are associated to form an electronic medical record. The electronic medical record, along with images and audio, is then transmitted over a communications network to update the central database.
<P>PROBLEM TO BE SOLVED: To provide powder having improved dispersibility, a paste comprising the powder and a cosmetic comprising the paste.  <P>SOLUTION: The powder is used for the paste for preparing the cosmetic and the surface thereof is subjected to a coating treatment with aluminum oxide hydrate and/or silicic acid. The oil gel cosmetic comprises the paste prepared by using the coated powder. Titanium dioxide or zinc oxide is preferred as substrate powder of the coated powder. The generation of radicals after absorbing ultraviolet rays is suppressed as accompanying effects.  <P>COPYRIGHT: (C)2005,JPO&NCIPI